A Phase II Study of Temsirolimus (Torisel) and Erlotinib (Tarceva) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase II Study of Temsirolimus (Torisel) and Erlotinib (Tarceva) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2015

At a glance

  • Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 18 Sep 2012 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
    • 29 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top